TTR and cardiac amyloidosis: TTR protein stabilizing therapy such as Tafamidis in patients with transthyretin cardiac amyloidosis has been shown to increase TTR levels by stabilizing the native tetrameric structure of TTR and decreasing the risk of mortality3,13.